Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis

NCT ID: NCT02848625

Last Updated: 2025-01-31

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-27
• Study Completion Date: 2025-12-31

Brief Summary

This study will evaluate whether regular yoga exercises designed specifically for patients with Idiopathic Pulmonary Fibrosis is associated with any change in quality of life. Half of the participants will be randomized to yoga, half to usual care. Yoga was conducted live, virtually, in the setting of the COVID Pandemic.

Detailed Description

Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic (scarring) disease of the lung of unknown cause. Approximately 100,000 Americans will die from IPF this year. There is no cure for IPF other than lung transplantation, which only 1% of patients will receive. Recently, 2 drugs were approved by the FDA to slow the rate of decline in lung function among patients with IPF. These drugs do not decrease symptoms or improve quality of life.

Symptoms of IPF include shortness of breath, cough, and fatigue, all of which may also adversely affect quality of life. Yoga is a practice of exercises, including breathing exercises, that has been shown to be relatively safe and to improve quality of life in some patients with other advanced lung diseases. We hypothesize that regular yoga and breathing exercises, specifically designed for patients with Idiopathic Pulmonary Fibrosis, over a period of 12 weeks will lead to improved quality of life as measured by several different quality of life questionnaires.

Conditions

Idiopathic Pulmonary Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Group A

Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF. Yoga sessions were virtual in the setting of the COVID Pandemic

Group Type: EXPERIMENTAL

Yoga

Intervention Type: OTHER

Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks

Group B

Patients who are not randomized to yoga sessions will continue with their usual care and usual activities

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Yoga

Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: Adults 18 years of age or older. We will include all consecutive consenting patients with IPF who are able to provide informed consent and are seen and followed at the Center for Interstitial Lung Disease at the University of Washington Medical Center.

Exclusion Criteria: Subjects with comorbid diseases that would prohibit them from taking part in yoga will be excluded at the discretion of the clinical-investigators. Such comorbid diseases would include paralysis, musculoskeletal discomfort that would interfere with participation or broken limbs. Since we are interested in the effect of yoga among subjects with IPF, we will exclude subjects who have previously received lung transplantation. To assess the effect "new" or "initial" participation in a yoga program with breathing exercises on quality of life, subjects who are regularly participating in yoga (outside of the study) will be excluded.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Washington

OTHER

Sponsor Role: lead

Responsible Party

Ganesh Raghu

Co-Principal Investigator (Ganesh Raghu, MD is Principal Investigator)

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ganesh Raghu, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington, Center for Interstitial Lung Diseases

Bridget F Collins, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington, Center for Interstitial Lung Diseases

Locations

University of Washington Medical Center

Seattle, Washington, United States

Countries

United States

Other Identifiers

51411-A

Identifier Type: -

Identifier Source: org_study_id